$GILD Company News Visa shares rise after hours on

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 1:08 PM

$GILD Company News

Visa shares rise after hours on earnings beat 6:50 p.m. Oct. 29, 2014 - Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing 8:34 a.m. Oct. 29, 2014 - Shawn Langlois
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
Sales of Gilead's pricey hepatitis C drug slow 4:26 p.m. Oct. 28, 2014 - MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss 4:14 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results 4:09 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln 4:08 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales top FactSet consensus estimate of $5.99 bln 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 sales $6.04 bln vs. $2.78 bln a year ago 4:07 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Q3 net EPS $1.67 vs. 47 cents a year ago 4:06 p.m. Oct. 28, 2014 - Tomi Kilgore
Gilead Sciences Q3 adj. EPS $1.84 vs. FactSet consensus $1.92 4:06 p.m. Oct. 28, 2014 - Tomi Kilgore
Two biotech leaders to watch 2:12 p.m. Oct. 28, 2014 - The Trading Deck
Charting a bullish year-end backdrop 12:13 p.m. Oct. 28, 2014 - Michael Ashbaugh
Charting a bullish year-end backdrop 11:53 a.m. Oct. 28, 2014 - Michael Ashbaugh
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
Energy, health care earnings to dominate week 5:02 a.m. Oct. 26, 2014 - Wallace Witkowski
Caution is still the word for speculators 3:12 p.m. Oct. 23, 2014 - The Trading Deck
10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert

Gilead Sciences - What Convinced Me To Become Bullish 27 min ago - Seeking Alpha
Gilead: Stay The Course 11:51 a.m. Today - Seeking Alpha
Three Attractively Priced Small Cap Biotech Stocks 11:45 a.m. Today - GuruFocus.com
Ireland Widens Corporate Tax Break 8:07 p.m. Nov. 4, 2014 - The Wall Street Journal Interactive Edition
Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid? 8:38 a.m. Nov. 4, 2014 - Seeking Alpha
'Fast Money' Recap: Lower Oil Prices a Warning Sign for Stocks 5:00 a.m. Nov. 4, 2014 - TheStreet.com
CNBC's Stock Pops & Drops From November 3: GoPro, Gilead Sciences And More 7:17 p.m. Nov. 3, 2014 - benzinga.com
Earnings Growth Strong As U.S. Trumps World 4:31 p.m. Nov. 3, 2014 - Investors Business Daily
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock 3:53 p.m. Nov. 3, 2014 - Seeking Alpha
Bristol-Myers preparing to follow Gilead's lead on HCV drug pricing 3:23 p.m. Nov. 3, 2014 - Seeking Alpha
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog 12:50 p.m. Nov. 3, 2014 - Zacks.com
Gilead: Slaying The Last Dragons Of Doubt? 12:18 p.m. Nov. 3, 2014 - Seeking Alpha
3 Stocks Dragging In The Drugs Industry 12:08 p.m. Nov. 3, 2014 - TheStreet.com
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks 11:57 a.m. Nov. 3, 2014 - TheStreet.com
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog 11:10 a.m. Nov. 3, 2014 - Zacks.com
Gilead's EPS Miss Is Investors' Gain: Gilead's A Buy On Harvoni Success 8:49 a.m. Nov. 3, 2014 - Seeking Alpha
Why Did Gilead Drop Friday? Is It Justified Or Just An Overreaction? 8:41 a.m. Nov. 3, 2014 - Seeking Alpha
Surging Earnings Estimates Signal Good News for Gilead (GILD) - Tale of the Tape 8:40 a.m. Nov. 3, 2014 - Zacks.com
Super Important Biotech and Drug Stock Events for November 8:24 a.m. Nov. 3, 2014 - TheStreet.com
Gilead Sciences has Multiple Growth Drivers 5:09 p.m. Oct. 31, 2014 - GuruFocus.com

Earnings Forecast Buzz for Alibaba, GT Advanced Technologies, GoPro, Plug Power, Gilead Sciences, and American Realty Capital Properties 8:45 a.m. Nov. 4, 2014 - PR Newswire - PRF
Life-Science New Build Report: 200 New North American Sites in Planning Represent Potential $15 Billion Investment, an Industrial Info News Alert 6:16 a.m. Nov. 4, 2014 - Marketwired
Gilead Sciences Once Again Tops the List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 6:15 a.m. Nov. 4, 2014 - Marketwired
Earnings Forecast Buzz for American Realty Capital Properties, Alibaba, Petroleo Brasileiro Petrobras SA, Gilead Sciences, RF Micro Devices, and GoPro 8:45 a.m. Oct. 30, 2014 - PR Newswire - PRF
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly 8:35 a.m. Oct. 29, 2014 - PR Newswire - PRF
Gilead Sciences Announces Third Quarter 2014 Financial Results 4:09 p.m. Oct. 28, 2014 - BusinessWire - BZX
Earnings Forecast Research for DryShips, GoPro, Gilead Sciences, MannKind, GT Advanced Technologies, and Amazon 8:45 a.m. Oct. 27, 2014 - PR Newswire - PRF
Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 5:00 p.m. Oct. 21, 2014 - BusinessWire - BZX
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fintech Shake-Up: OPay's $4B NYSE IPO Arrival

It's a big day on Wall Street as OPay dives into the NYSE with a hefty market cap of over $4 billion, signaling a major moment for the fintech arena. Oh, how times are shifting! Today marks the debut of OPay under the ticker 'OPAY,' and let me tell you, there's a buzz in the air that could quicken any seasoned trader's pulse. OPay's Big Day: A New Era of Fintech Their...

AI, GLP-1, and the Food Revolution Unveiled

By Evelyn Baker Updated Oct 29, 2026 Category News Views 147

How the Food Industry Faces a Formulation Shake-Up In a world where diets are shifting like never before, food companies are adjusting their game plans or risk getting left in the dust. With one in five U.S. households reportedly housing a GLP-1 user by May 2026, the food game looks more like a strategic chess match than ever. Balancing taste, nutrition, and price is no...

Mondel?z Bites into Undercover: Snack Market Impact

Snack World Shake-Up: Mondel?z Steps In Ever find yourself browsing the snack aisle, wondering how many brands are duking it out for shelf space? Well, brace yourself, because Mondel?z International — the big cheese in the global snack game — is grabbing a sizeable bite of Undercover Snacks. This is no small news in the land of chocolate-covered and frosted quinoa...

Cboe's Third Quarter Packs a Punch with Strong Gains

Making Waves in the Market There's no sugar-coating it—Cboe Global Markets has had a hell of a third quarter in 2026. With their diluted EPS climbing to a record $4.08, a 43% jump from last year, it's no surprise their stock ticker, CBOE, is catching some eyes. Adjusted diluted EPS also made a splash, soaring 36% to $3.63 compared to 2025 figures. Their strategic moves...

ACACIA's Big Move with Bel-Mac and Seashore: Will It Pay Off?

A New Powerhouse in Roofing Services? Take a seat, folks—we're talking about a regional shakeup in the world of roofing and exterior building. ACACIA Exterior Building Group, based out of Alexandria, Virginia, just tightened its grip on the Mid-Atlantic and Gulf Coast markets by investing in Bel-Mac Roofing and Seashore Construction. This ain't just your run-of-the-mill...

Scientology Ministers Train First Responders in Philippines

Boots on the Ground: Scientology's Goodwill Tour In a world where chaos often reigns supreme, it's refreshing to see someone step up to support those who stare down danger daily. The Scientology Volunteer Ministers have taken it upon themselves to empower those on the front lines in the Philippines. From bustling Manila to the calmer waves of Davao City, these ministers...

Alfa Laval Secures EUR 1B Credit Facility Extension

Alfa Laval Banks on a New Financial Horizon Forget your morning rituals, Alfa Laval just pulled off a maneuver that's got industry tongues wagging. Thanks to a new EUR 1 billion revolving credit facility, they've bolstered their financial defenses, setting a robust foundation for the future. The facility, no dink-and-dunk affair, carries an initial five-year maturity. And...

Embraer ADS Ratio Change: Impact on Investors

ADS Ratio Adjustments: What's the Big Deal? Well, here we go. Embraer, that Brazilian aerospace heavyweight, has just kicked up some dust with its latest move concerning American Depositary Shares (ADS). Now, don't expect any shock and awe value-explosion gimmicks, but there's a shift in the air. Understanding the Split Let's cut to the financial meat: Embraer’s mucking...

Modular Building Boom Shakes Up Asian Construction

Building the Future, One Module at a Time What's ticking in the world of construction? Modular buildings, my friends. They're generating buzz at the Fourth Linyi Mall International Buyers Conference held last week, and for good reasons. If you're not following, China is rolling out prefabricated houses like they're the next big thing since sliced bread, leaving buyers in...

Barco Brings HDR Cinema Home with Kinepolis Kortrijk

A New Chapter in Cinema Projection Ah, Belgium, the land of waffles and apparently, cutting-edge cinema tech. That's right, Barco is bringing their HDR by Barco system to its own backyard in Kortrijk, teaming up with Kinepolis to shake things up. It's not just any expansion—it's a homecoming of sorts. The company's laser cinema magic has already made face time in the...